

6<sup>th</sup> November, 2020

To  
The General Manager,  
Department of Corporate Relations,  
BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai - 400001

Dear Sir,

**Scrip Code: 536565**

**Sub: Outcome of Board Meeting dated 6<sup>th</sup> November, 2020 and Disclosure as per Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

We wish to inform you that at the meeting of the Board of Directors of the Company held today i.e. on Friday, 6<sup>th</sup> November, 2020, the Board of Directors of the Company have inter-alia considered, approved the following:

1. Took on record the unaudited standalone and consolidated financial results of the Company for the quarter ended 30<sup>th</sup> September, 2020. The said unaudited financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors.

The Statutory Auditors have carried out a "Limited Review" of the unaudited Financial Results for the quarter ended 30<sup>th</sup> September 2020.

2. In continuation to our letter vide dated 29<sup>th</sup> July, 2020, this is to inform that the Company has received food license and has started sales of drug, food and ayurvedic products.


In compliance with Regulations 33 & Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the Standalone and Consolidated Financial Results and Limited Review Report of the Statutory Auditors of the Company.

The Board Meeting commenced at 03:00 p.m. and concluded at 05:00 p.m.

This is for your information and records.

Thanking you,  
Yours faithfully,

For Trimurthi Limited,

  
(Arun Kumar Bhargava)  
Managing Director  
DIN: 00021024

Encl: As above

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Indrabagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

**Independent Auditor's Review Report on the Quarterly Unaudited Ind AS Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To**  
**The Board of Directors**  
**Trimurthi Limited:**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of M/s TRIMURTHI LIMITED ("the Company") for the quarter and half year ended September 30, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019
2. The preparation of "the Statement", which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We have conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

4. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S



A Krishna Rao  
Partner  
M.No. 020085  
UDIN: 20020085AAAATI6097

Place: Hyderabad  
Date: 06-11-2020





TRIMURTHI  
GROUP

TRIMURTHI LIMITED  
4-4-231/1/2/ABC, Inner Bagh, Sultan Bazar, Hyderabad - 500085.  
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS  
FOR THE QUARTER END AND HALF YEAR ENDED 30TH SEPTEMBER 2020

(Amount in lakhs except EPS)

PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	30.09.2020 (UNAUDITED)	30.09.2020 (UNAUDITED)	30.09.2019 (UNAUDITED)	30.09.2020 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.03.2020 (AUDITED)
INCOME FROM OPERATIONS	30.31	24.10	34.73	54.31	33.86	103.33
OTHER INCOME	6.40	11.22	8.26	17.62	29.00	47.31
<b>TOTAL INCOME</b>	<b>36.71</b>	<b>35.32</b>	<b>43.00</b>	<b>71.93</b>	<b>62.86</b>	<b>150.64</b>
<b>2. EXPENSES</b>						
PURCHASES	28.32	28.83	18.37	57.15	36.47	75.21
COST OF MATERIALS CONSUMED	-	-	-	-	-	-
MANUFACTURING EXPENSES	-	-	-	-	-	-
WORK IN PROGRESS AND STOCK IN TRADE	0.17	(2.40)	1.32	(2.23)	(0.33)	2.44
RENT	0.40	0.20	0.00	0.60	0.00	1.95
EMPLOYEE BENEFITS EXPENSE	0.72	6.28	7.30	10.80	12.94	38.50
FINANCE COSTS	-	-	-	-	-	-
DEPRECIATION AND AMORTISATION EXPENSES	2.14	2.10	1.97	4.32	4.44	7.62
OTHER EXPENSES	0.43	0.71	4.33	10.14	13.22	39.10
<b>TOTAL EXPENSES</b>	<b>33.18</b>	<b>41.80</b>	<b>34.76</b>	<b>84.98</b>	<b>66.43</b>	<b>179.89</b>
<b>ITEMS (1-2)</b>	<b>(6.47)</b>	<b>(6.48)</b>	<b>(11.76)</b>	<b>(13.06)</b>	<b>(7.56)</b>	<b>30.65</b>
<b>3. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS</b>						
<b>5. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (3-4)</b>	<b>(6.47)</b>	<b>(6.48)</b>	<b>(11.76)</b>	<b>(13.06)</b>	<b>(7.56)</b>	<b>10.65</b>
<b>4. TAX EXPENSES</b>						
CURRENT TAX	0.00	0.07	0.00	0.13	0.05	1.17
TAX ADJUSTMENTS RELATING TO EARLIER YEARS	-	-	-	-	-	0.04
DEFERRED TAX (NET)	0.00	0.07	0.00	0.13	0.25	0.23
<b>7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (5-6)</b>	<b>(6.47)</b>	<b>(6.41)</b>	<b>(10.34)</b>	<b>(12.80)</b>	<b>(7.26)</b>	<b>9.49</b>
<b>8. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS</b>						
<b>9. TAX EXPENSES FOR DISCONTINUED OPERATIONS</b>						
<b>10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)</b>						
<b>11. PROFIT/(LOSS) FOR THE PERIOD (7+10)</b>	<b>(6.47)</b>	<b>(6.41)</b>	<b>(10.34)</b>	<b>(12.80)</b>	<b>(7.26)</b>	<b>9.49</b>
<b>12. OTHER COMPREHENSIVE INCOME</b>						
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	-	0.11	0.67	0.11	(1.23)	(1.43)
(ii) INCOME TAX RELATING TO ITEM THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS						
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
(ii) INCOME TAX RELATING TO ITEM THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
<b>13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT/(LOSS) AND OTHER COMPREHENSIVE INCOME)</b>	<b>(6.47)</b>	<b>(6.30)</b>	<b>(9.67)</b>	<b>(12.69)</b>	<b>(8.49)</b>	<b>8.06</b>
<b>14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATIONS):</b>						
(a) BASIC	(0.08)	(0.08)	(0.13)	(0.16)	(0.09)	0.12
(b) DILUTED	(0.08)	(0.08)	(0.13)	(0.16)	(0.09)	0.12
<b>15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATIONS):</b>						
(a) BASIC						
(b) DILUTED						
<b>16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATIONS):</b>						
(a) BASIC	(0.08)	(0.08)	(0.13)	(0.16)	(0.09)	0.12
(b) DILUTED	(0.08)	(0.08)	(0.13)	(0.16)	(0.09)	0.12

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inner Bagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**TRIMURTHI**  
GROUP

**TRIMURTHI LIMITED**  
SCHEDULE III OF THE COMPANIES ACT 2013  
PART-B

PARTICULARS	QUARTER ENDED			Half Year Ended		YEAR ENDED
	30.09.2020 (UNAUDITED)	30.06.2020 (UNAUDITED)	30.09.2019 (UNAUDITED)	30.09.2020 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.03.2020 (AUDITED)
<b>PARTICULARS OF SHARE HOLDING</b>						
<b>A. Public Share Holding</b>						
1. - Number of Shares	290000	290000	290000	290000	290000	290000
- Percentage of shareholding	35.81%	35.81%	35.81%	35.81%	35.81%	35.81%
2. - Promoters and promoter group shareholding						
a. Promoter / Promoter group						
- No. of Equity Shares	750	750	750	750	750	750
- Percentage of Shares for the shareholding of promoter and promoter group	0.26%	0.26%	0.26%	0.26%	0.26%	0.26%
- Percentage of Shares for the total share capital of the company	0.26%	0.26%	0.26%	0.26%	0.26%	0.26%
b. Non-promoter						
- No. of Equity Shares	219940	219940	219940	219940	219940	219940
- Percentage of Shares for the shareholding of promoter and promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares for the total share capital of the company	84.19%	84.19%	84.19%	84.19%	84.19%	84.19%
<b>Particulars</b>	<b>3 Months Ended : 30/09/2020</b>					
<b>B. Investor Complaints</b>						
a. Pending at the beginning of the quarter		-Nil-				
Received during the quarter		-Nil-				
Unresolved during the quarter		-Nil-				
Remaining unresolved during the quarter		-Nil-				

**TRIMURTHI LIMITED**

**Segment Reporting**

PARTICULARS	QUARTER ENDED			Half Year Ended		YEAR ENDED
	30.09.2020 (UNAUDITED)	30.06.2020 (UNAUDITED)	30.09.2019 (UNAUDITED)	30.09.2020 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.03.2020 (AUDITED)
<b>Segment Revenue</b>						
<b>I. a. Pharma Business</b>	-	-	-	-	-	-
b. Financial Services	5.44	7.44	8.21	12.88	21.09	42.56
c. Investments	0.96	3.78	0.06	4.74	3.91	6.33
d. Trading in Shares	30.21	24.10	14.73	54.31	33.86	107.45
e. Foods	-	-	-	-	-	-
<b>Total</b>	<b>36.61</b>	<b>150.54</b>	<b>23.00</b>	<b>71.93</b>	<b>58.86</b>	<b>156.54</b>
<b>Less: Inter Segment Revenue</b>	-	-	-	-	-	-
<b>Net Segment Profit (Before tax &amp; Interest from Each Segment)</b>	<b>36.61</b>	<b>150.54</b>	<b>23.00</b>	<b>71.93</b>	<b>58.86</b>	<b>156.54</b>
<b>II. a. Pharma Business</b>	-	-	-	-	-	-
b. Financial Services	5.44	7.44	8.21	12.88	21.09	42.56
c. Investments	0.96	3.78	0.06	4.74	3.91	6.33
d. Trading in Shares	30.21	24.10	14.73	54.31	33.86	107.45
e. Foods	-	-	-	-	-	-
<b>Total</b>	<b>36.61</b>	<b>150.54</b>	<b>23.00</b>	<b>71.93</b>	<b>58.86</b>	<b>156.54</b>
<b>Less: Interest</b>	-	-	-	-	-	-
<b>III. a. Other Unallocable expenses net off</b>	-	-	-	-	-	-
<b>IV. Unallocable Income</b>	-	-	-	-	-	-
<b>Total Profit Before Tax</b>	<b>36.61</b>	<b>150.54</b>	<b>23.00</b>	<b>71.93</b>	<b>58.86</b>	<b>156.54</b>
<b>V. a. Pharma Business</b>	29.50	29.50	-	29.50	-	29.50
b. Financial Services	547.45	247.40	546.22	549.82	546.22	547.96
c. Investments	29.82	13.61	259.88	29.82	259.88	23.18
d. Trading in Shares	485.11	580.68	373.75	485.11	373.75	486.44
e. Foods	300.00	300.00	12.34	300.00	12.34	300.00
<b>Total</b>	<b>1,194.28</b>	<b>1,200.69</b>	<b>1,192.19</b>	<b>1,194.28</b>	<b>1,192.19</b>	<b>1,207.28</b>

Notes:

The format for the Audited quarterly results as prescribed in SEBI Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CIR/CFD/FAC/62/2016 dated July 5, 2016.

- Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 06-11-2020.
- The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules, issued there under and the other accounting principles generally accepted in India.

New: Hyderabad  
Date: 06-11-2020

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/A8C, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**TRIMURTHI LIMITED**  
Standalone Statement of Assets and Liabilities



(Amount in Lakhs)		
Particulars	Half Year Ended 30-09-2020	Year Ended 31-03-2020
<b>ASSETS</b>		
<b>1 Non Current Assets</b>		
a Property, Plant and Equipments	26.57	30.82
b Capital Work In Progress	-	-
c Investment Property	-	-
d Goodwill	-	-
e Other Intangible Assets:	0.00	0.08
f Intangible Assets under development	-	-
g Biological assets other than bearer plants	-	-
<b>h Financial Assets:</b>		
Investments	359.32	352.68
Trade Receivables	-	-
Loans	-	-
Others	-	-
Loans	-	-
Others	-	-
i Deferred Tax Assets (net)	-	-
Other Non Current Assets	20.00	20.00
<b>Total Non Current Assets</b>	<b>405.90</b>	<b>403.58</b>
<b>2 Current Assets</b>		
a Inventories	10.03	7.83
b Financial Assets	-	-
Investments	-	-
Trade Receivables	7.90	228.32
Cash and Cash Equivalents	180.08	95.23
Bank balances other than above	-	-
Loans	349.85	367.98
Others	-	-
c Current Tax Assets (net)	-	-
d Other Current Assets	238.64	101.05
<b>Total Current Assets</b>	<b>786.53</b>	<b>800.40</b>
<b>Total Assets</b>	<b>1,192.42</b>	<b>1,203.98</b>
<b>EQUITY AND LIABILITIES</b>		
<b>1 Equity</b>		
a Equity Share Capital	810.00	810.00
b Other Equity	384.28	397.10
<b>Total - Equity</b>	<b>1,194.29</b>	<b>1,207.10</b>
<b>2 Liabilities</b>		
<b>Non Current Liabilities</b>		
a Financial Liabilities	-	-
Borrowings	-	-
Trade Payables	-	-
Other Financial Liabilities	-	-
b Provisions	-	-
c Deferred Tax Liabilities (net)	(5.98)	(5.85)
d Other Non Current Liabilities	-	-
<b>Total Non Current Liabilities</b>	<b>(5.98)</b>	<b>(5.85)</b>
<b>Current Liabilities</b>		
a Financial Liabilities	-	-
Borrowings	-	-
Trade Payables	2.33	0.67
Other Financial Liabilities	-	-
b Other Current Liabilities	1.59	1.42
c Provisions	-	-
d Current Tax Liabilities (net)	-	0.64
<b>Total Current Liabilities</b>	<b>4.12</b>	<b>2.73</b>
<b>Total - Equity and Liabilities</b>	<b>1,192.42</b>	<b>1,203.98</b>

**TRIMURTHI LIMITED**  
(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
44-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email: info@trimurthidrugs.com  
Website: www.trimurthidrugs.com  
CIN No: L67120TG1994PLC018956

For Trimurthi Ltd  
Arun Kumar Bhargava  
Managing Director  
Din No: 00021024





**TRIMURTHI LIMITED**

4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad-500095.

**TRIMURTHI**  
GROUP**STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 30TH SEPT, 2020**

(Rs. In Lakhs)

Particulars	As at 30.09.2020	As at 31.03.2020
<b>A. Cash Flow from Operating Activities:</b>		
Net Profit before Tax and Extraordinary Items	(13.06)	10.65
Adjustments for:		
Depreciation	4.32	7.82
Interest & Other Income	(11.58)	(38.98)
Profit/Loss on Sale of Investments & Property	(4.74)	(4.53)
Operating profit before Working Capital Changes	(25.05)	(25.03)
Adjustments for:		
Trade and Other receivables	100.96	159.33
Inventories	(2.23)	3.19
Trade payables	2.03	(11.88)
Cash generated from Operations	100.76	150.64
Cash flow before Extraordinary Items	75.71	125.61
Extraordinary Items and Tax	(0.64)	(4.49)
Net Cash used for Operating activities	75.07	121.13
<b>B. Cash Flow from Investing Activities:</b>		
Purchase of Fixed Assets	0.00	(1.49)
Sale of Fixed Assets	0.00	0.00
Capital Work in progress	0.00	0.00
Purchase / Sale of Investments	(1.79)	(79.42)
Increase / (Decrease) in Security Deposits	0.00	0.00
Interest & Other Income	11.58	38.98
Net Cash flow from Investing activities	9.78	(41.93)
<b>C. Cash Flow from Financing Activities:</b>		
Increase in Share Capital	0.00	0.00
Increase in Share Premium	0.00	0.00
Increase / Decrease in Long Term Borrowings	0.00	0.00
Share Issue and Preliminary Expenses	0.00	0.00
Dividends Paid	0.00	0.00
Net Cash flow from Financing activities	0.00	0.00
Net Increase in Cash and Cash Equivalents	84.85	79.19
Cash and Cash Equivalents as at (Opening Balance)	95.23	16.03
Cash and Cash Equivalents as at (Closing Balance)	180.08	95.23

For Trimurthi Limited

Arun Kumar Bhangadia

Managing Director

DIN No. 00021024

Place: Hyderabad

Date: 06-11-2020

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs &amp; Pharmaceuticals Ltd.)

4-4-231/1/2/ABC, Inderbagh, Sultanbazar,

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email : info@trimurthidrugs.com

Website : www.trimurthidrugs.com

CIN No : L67120TG1994PLC018956





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

**Independent Auditor's Review Report on the Quarterly Unaudited Ind AS Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended**

To  
The board of directors  
**Trimurthi Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of TRIMURTHI LIMITED (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended Sep 30, 2020 and for the period from 01-04-2020 to 30-09-2020 ("the Statement"), being submitted by the "Holding Company" pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on "the Statement" based on our review.

We conducted our review of "the Statement" in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether "the Statement" is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

"The Statement" includes the Ind AS financial results of the following entities:

a) Trimurthi Foods

b) Trimurthi Pharmaceuticals (India) Private Limited

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.

Chartered Accountants

FRN: 007257S


A Krishna Rao

Partner

M.No. 020085

UDIN: 20020085AAAATJ6878

Place: Hyderabad

Date: 06-11-2020.



**TRIMURTHI**  
GROUP

**TRIMURTHI LIMITED**  
**SCHEDULE III OF THE COMPANIES ACT 2013**  
**CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020**

(Amount in Lakhs Except EPS)

PART-I

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>I. Income From Operations</b>						
Net Sales / Income from Operations	248.47	205.47	262.36	453.94	505.94	1074.44
Other Income	6.54	11.81	20.18	18.36	24.43	60.11
<b>II. Total Income</b>	<b>255.01</b>	<b>217.28</b>	<b>282.54</b>	<b>472.30</b>	<b>530.37</b>	<b>1084.55</b>
<b>III. Expenses</b>						
a. Consumption of Raw Material	56.22	46.09	55.98	102.31	67.86	211.84
b. Purchase of Traded Goods/Shares	125.64	101.80	154.42	217.43	292.33	532.23
c. (Increase)/Decrease in stock in trade and work in Progress	3.04	(0.54)	(0.10)	5.11	(9.95)	(9.45)
d. Manufacturing Expenses	45.17	37.31	54.39	83.08	103.62	162.25
e. Employee benefits expense	26.60	22.55	26.24	51.15	48.88	96.40
f. Rent	1.50	1.40	1.50	3.00	3.00	6.75
g. Finance Cost	2.06	2.20	2.67	4.32	6.57	11.45
h. Depreciation	2.50	4.95	4.73	7.45	10.66	19.14
i. Other Expenditure	10.26	10.79	10.79	21.04	25.36	55.52
<b>Total</b>	<b>267.69</b>	<b>227.20</b>	<b>300.13</b>	<b>494.69</b>	<b>588.63</b>	<b>1106.04</b>
<b>IV. Profit/(Loss) before Exceptional and Tax (II-III)</b>	<b>(12.68)</b>	<b>(9.92)</b>	<b>(17.69)</b>	<b>(22.40)</b>	<b>(18.00)</b>	<b>(21.50)</b>
<b>V. Exceptional Items/Prior Period Items</b>						
<b>VI. Profit/(Loss) before tax (IV-V)</b>	<b>(12.68)</b>	<b>(9.92)</b>	<b>(17.69)</b>	<b>(22.40)</b>	<b>(18.00)</b>	<b>(21.50)</b>
<b>VII. Tax expense</b>	<b>2.54</b>	<b>(0.96)</b>	<b>(0.50)</b>	<b>1.38</b>	<b>3.15</b>	<b>4.81</b>
(1) Current tax	1.28	0.00	(0.96)	1.24	1.21	1.74
(2) Deferred tax	1.26	(0.96)	0.46	0.14	0.94	1.68
<b>VIII. Net Profit/(Loss) for the period from continuing operations (VI-VII)</b>	<b>(10.14)</b>	<b>(8.95)</b>	<b>(17.19)</b>	<b>(24.18)</b>	<b>(18.22)</b>	<b>(25.91)</b>
<b>IX. Profit/(Loss) from discontinued operations</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>
<b>X. Tax expenses of discontinued operations</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>
<b>XI. Profit/(Loss) from Discontinued operations (after tax) (IX-X)</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>
<b>XII. Profit/(Loss) for the period (VIII+XI)</b>	<b>(10.14)</b>	<b>(8.95)</b>	<b>(17.19)</b>	<b>(24.18)</b>	<b>(18.22)</b>	<b>(25.91)</b>
<b>XIII. Other Comprehensive Income</b>						
A. (i) Items that will not be reclassified to profit or loss	0.00	0.11	0.67	0.11	(1.23)	(3.42)
(ii) Income tax relating to items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
B. (i) Items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>XIV. Total Comprehensive Income for the period (XII+XIII) comprising Profit/(Loss) and Other comprehensive income for the period</b>	<b>(10.14)</b>	<b>(8.83)</b>	<b>(16.52)</b>	<b>(24.07)</b>	<b>(19.45)</b>	<b>(29.34)</b>
<b>XV. Minority Interest</b>	<b>1.65</b>	<b>(0.34)</b>	<b>0.10</b>	<b>1.31</b>	<b>1.22</b>	<b>2.43</b>
<b>XVI. Total Comprehensive Income for the period after Minority Interest (XIV-XV)</b>	<b>(16.87)</b>	<b>(9.50)</b>	<b>(16.63)</b>	<b>(25.38)</b>	<b>(20.67)</b>	<b>(31.78)</b>
<b>XVII. Earnings per equity share (for continuing operations)</b>						
(1) Basic	(0.21)	(0.11)	(0.23)	(0.31)	(0.24)	(0.33)
(2) Diluted	(0.21)	(0.11)	(0.21)	(0.31)	(0.24)	(0.35)
<b>XVIII. Earnings per equity share (for discontinuing operations)</b>						
(1) Basic	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(2) Diluted	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>XIX. Earnings per equity share (for discontinuing &amp; continuing operations)</b>						
(1) Basic	(0.21)	(0.11)	(0.21)	(0.31)	(0.28)	(0.33)
(2) Diluted	(0.21)	(0.11)	(0.21)	(0.31)	(0.24)	(0.35)

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/A8C, Indrabagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**TRIMURTHI LIMITED**  
**SCHEDULE III OF THE COMPANIES ACT 2013**

**PART-B**

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30/09/2020	30/09/2019	30/09/2018	30/09/2020	30/09/2019	31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A. Particulars Of Share Holding</b>						
1. Public Share Holding						
- Number of Shares	2900600	2900600	2900600	2900600	2900600	2900600
- Percentage of shareholding	35.81%	35.81%	35.18%	35.18%	35.18%	35.81%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the shareholding of promoter and promoter group)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
b. Non-encumbered						
- No of Equity Shares	5199400	5199400	5199400	5199400	5199400	5199400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	64.19%	64.19%

Particulars	3 Months Ended (30/09/2020)
<b>B. Investor Complaints</b>	
Pending at the beginning of the quarter	-Nil-
Received during the quarter	-Nil-
Disposed during the quarter	-Nil-
Remaining unresolved during the quarter	-Nil-

**Segment Reporting**

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30/09/2020	30/09/2019	30/09/2018	30/09/2020	30/09/2019	31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment Revenue						
a. Pharma Business	110.58	83.29	148.96	194.17	279.86	535.27
b. Financial Services	5.48	8.04	7.59	13.51	20.27	47.73
c. Investments	0.96	3.78	(0.07)	4.74	5.78	4.53
d. Foods	107.79	97.78	111.09	205.37	192.25	393.06
e. Trading in Shares	30.21	24.10	15.08	34.31	34.21	103.45
<b>Total</b>	<b>255.01</b>	<b>217.29</b>	<b>282.64</b>	<b>472.50</b>	<b>530.37</b>	<b>1084.55</b>
Less: Inter Segment Revenue	-Nil-	-Nil-	0.00	-Nil-	-Nil-	-Nil-
<b>Net Sales/ Income from Operations</b>	<b>255.01</b>	<b>217.29</b>	<b>282.64</b>	<b>472.50</b>	<b>530.37</b>	<b>1084.55</b>
2. Segment Profit ( Before tax & Interest from Each Segment)						
a. Pharma Business	6.05	(1.07)	0.39	4.08	8.34	8.39
b. Financial Services	3.41	5.79	14.09	9.19	20.27	26.28
c. Investments	0.96	3.78	(0.07)	4.74	5.78	4.53
d. Foods	(10.13)	0.30	1.12	(9.93)	(12.22)	(32.38)
e. Trading in Shares	(12.97)	(17.79)	(25.97)	(30.67)	(32.23)	(26.44)
<b>Total</b>	<b>(12.68)</b>	<b>(9.92)</b>	<b>(17.69)</b>	<b>(22.60)</b>	<b>(16.06)</b>	<b>(21.98)</b>
Less:						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Unallocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Unallocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>(12.68)</b>	<b>(9.92)</b>	<b>(17.69)</b>	<b>(22.60)</b>	<b>(16.06)</b>	<b>(21.98)</b>
3. Capital Employed						
a. Pharma Business	77.27	71.89	84.70	77.27	84.70	75.39
b. Financial Services	549.85	267.00	449.46	549.85	449.46	367.08
c. Investments	29.82	13.61	37.14	29.82	37.14	23.18
d. Foods	62.47	105.60	189.09	62.47	189.09	107.31
e. Trading in Shares	485.11	590.68	311.31	485.11	311.60	496.44
<b>Total</b>	<b>1204.52</b>	<b>1081.79</b>	<b>1071.39</b>	<b>1204.52</b>	<b>1071.39</b>	<b>1060.29</b>

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**Notes**



**TRIMURTHI**  
GROUP

1. Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 06-11-2020.
3. The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-As) as notified by Ministry of Corporate Affairs, Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter and half year ended 30th September, 2020. The Ind AS Complaint figures for the Corresponding previous Quarter ended 31st March, 2019 have not been subject to review or audit, however the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
4. The results are also available on the website of the Company.

Place : Hyderabad

Date : 06-11-2020



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**TRIMURTHI LIMITED**  
Consolidated Statement of Assets and Liabilities



**TRIMURTHI**  
GROUP

		(Amount in Lakhs)	
	Particulars	Half Year Ended 30-09-2020	Year Ended 31-03-2020
<b>ASSETS</b>			
<b>1 Non Current Assets</b>			
a	Property, Plant and Equipments	173.50	177.69
b	Capital Work In Progress	-	-
c	Investment Property	-	-
d	Goodwill	-	-
e	Other Intangible Assets	4.95	5.50
f	Intangible Assets under development	-	-
g	Biological assets other than bearer plants	-	-
h	Financial Assets:		
	Investments	30.30	29.66
	Trade Receivables	-	-
	Loans	-	-
	Others	-	-
	Loans	-	-
	Others	-	-
i	Deferred Tax Assets (net)	-	-
	Other Non Current Assets	21.08	20.15
	<b>Total Non Current Assets</b>	<b>234.83</b>	<b>233.00</b>
<b>2 Current Assets</b>			
a	Inventories	92.61	90.68
b	Financial Assets:		
	Investments	-	-
	Trade Receivables	117.29	361.34
	Cash and Cash Equivalents	340.42	111.78
	Bank Balances other than above	-	-
	Loans	281.85	443.00
	Others	277.21	140.40
c	Current Tax Assets (net)	-	-
d	Other Current Assets	-	-
	<b>Total Current Assets</b>	<b>1,113.34</b>	<b>1,139.21</b>
	<b>Total Assets</b>	<b>1,358.17</b>	<b>1,372.21</b>
<b>EQUITY AND LIABILITIES</b>			
<b>1 Equity</b>			
a	Equity Share Capital	810.00	810.00
b	Other Equity	234.92	250.29
	<b>Total - Equity</b>	<b>1,034.92</b>	<b>1,060.29</b>
	Non Controlling Interest	53.78	52.48
<b>2 Liabilities</b>			
<b>Non Current Liabilities</b>			
a	Financial Liabilities		
	Borrowings	68.64	76.72
	Trade Payables	-	-
	Other Financial Liabilities	-	-
b	Provisions	-	-
c	Deferred Tax Liabilities (net)	2.24	1.90
d	Other Non Current Liabilities	-	-
	<b>Total Non Current Liabilities</b>	<b>70.88</b>	<b>78.62</b>
<b>Current Liabilities</b>			
a	Financial Liabilities		
	Borrowings	-	-
	Trade Payables	158.68	164.81
	Other Financial Liabilities	-	-
b	Other Current Liabilities	30.67	13.28
c	Provisions	-	-
d	Current Tax Liabilities (net)	1.24	2.71
	<b>Total Current Liabilities</b>	<b>190.59</b>	<b>188.82</b>
	<b>Total - Equity and Liabilities</b>	<b>1,358.17</b>	<b>1,372.21</b>

Place: **TRIMURTHI LIMITED**

Date: 06-10-2020  
Only known as Trimurthi Drugs & Pharmaceuticals Ltd.]  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email: info@trimurthidrugs.com  
Website: www.trimurthidrugs.com  
CIN No: L87120TG1994PLC018956

For Trimurthi Ltd  
Arun Kumar Bhargava  
Managing Director  
Din No. 00021024



# TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad-500095.



TRIMURTHI  
GROUP

## CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 30TH SEPT, 2020

(Rs. In Lakhs)

Particulars	As at 30.09.2020	As at 31.03.2019
<b>A. Cash Flow from Operating Activities:</b>		
Net Profit before Tax and Extraordinary Items	(22.60)	(21.50)
Adjustments for:		
Depreciation	7.45	19.14
Interest & Other Expense	4.32	11.45
Interest & Other Income	(12.98)	(46.14)
Miscellaneous Exp Write-off	0.08	0.15
(Profit)/Loss on Sale of Assets		
(Profit)/Loss on Sale of Investments	(4.74)	(4.53)
Operating profit before Working Capital Changes	(28.46)	(41.43)
Adjustments for:		
Trade and Other receivables	260.43	36.00
Inventories	(1.92)	(11.29)
Trade payables	11.26	89.98
Cash generated from Operations	269.77	114.69
Cash flow before Extraordinary Items	241.31	73.26
Extraordinary Items and Tax	(2.74)	(10.51)
Net Cash used for Operating activities	238.57	62.76
<b>B. Cash Flow from Investing Activities:</b>		
Purchase of Fixed Assets	(2.72)	(10.58)
Sale of Fixed Assets	0.00	0.00
Capital Work in progress	0.00	0.00
Purchase/Sale of Investments	(1.79)	20.58
Increase / (Decrease) in Deposits	0.00	0.75
Interest & Other Income	8.66	34.69
Net Cash flow from Investing activities	4.14	45.45
<b>C. Cash Flow from Financing Activities:</b>		
Increase in Share Capital	-Nil-	-Nil-
Increase in Share Premium	-Nil-	-Nil-
Increase / Decrease in Long Term Borrowings	(8.08)	(16.35)
Share Issue and Preliminary Expenses	-Nil-	-Nil-
Dividends Paid	-Nil-	-Nil-
Capital Contribution from Minority Interest	-Nil-	-Nil-
Net Cash flow from Financing activities	(8.08)	(16.35)
<b>Net Increase in Cash and Cash Equivalents</b>	<b>234.64</b>	<b>91.85</b>
Cash and Cash Equivalents as at (Opening Balance)	111.78	19.93
Cash and Cash Equivalents as at (Closing Balance)	346.42	111.78

For Trimurthi Limited

*Arun Kumar*  
Arun Kumar Bhangadia

Managing Director

DIN No. 00021024



### TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)

4-4-231/1/2/ABC, Inderbagh, Sultanbazar,

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email : info@trimurthidrugs.com

Website : www.trimurthidrugs.com

CIN No. : L67120TG1994PLC018956